Preventive and early therapeutic effects of β-Glucan on the bleomycin-induced lung fibrosis in rats

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 8, 2015, Pages 1505-1516

  Iraz, M ^a,d   Bilgic, S ^b   Samdanci, E ^c   Ozerol, E ^c   Tanbek, K ^c  

^a ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

^c INONU UNIVERSITY   (Turkey)

^d BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Bleomycin; Glutathione; Hydroxyproline; Lung fibrosis; Therapeutic; glucan

Indexed keywords

ACETYLCYSTEINE; BETA GLUCAN; BIOLOGICAL MARKER; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROXYPROLINE; MALONALDEHYDE; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; ANTIOXIDANT; BLEOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BARLEY; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIZATION; INNATE IMMUNITY; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RAT; THERAPY EFFECT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; PULMONARY FIBROSIS; SPRAGUE DAWLEY RAT; TIME; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; BETA-GLUCANS; BLEOMYCIN; MALE; OXIDATIVE STRESS; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942240281     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. RAGHU G, COLLARD HR, EGAN JJ, MARTINEZ FJ, BEHR J, BROWN KK, COLBY TV, CORDIER JF, FLAHERTY KR, LASKY JA, ET AL. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence- based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. RAGHU G, WEYCKER D, EDELSBERG J, BRADFORD WZ, OSTER G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
3. WANG HD, YAMAYA M, OKINAGA S, JIA YX, KAMANAKA M, TAKAHASHI H, GUO LY, SASAKI H. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 2002; 165: 406-411.
4. BOROK Z, BUHL R, GRIMES GJ, BOKSER AD, HUBBARD RC, HOLROYD KJ, ROUM JH, CZERSKI DB, CANTIN AM, CRYSTAL RG. Effect of glutathione aerosol on oxidant- antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-216.
5. BOWLER RP, NICKS M, WARNICK K, CRAPO JD. Role of extracellular superoxide dismutase in bleomycininduced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 282: 719-726.
6. KING TE JR, SAFRIN S, STARKO KM, BROWN KK, NOBLE PW, RAQHU G, SCHWARTZ DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
7. BEHR J, MAIER K, DEGENKOLB B, KROMBACH F, VOGELMEIER C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-1901.
8. YILDIRIM Z, KOTUK M, IRAZ M, KUKU I, ULU R, ARMUTCU F, OZEN S. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: Erdosteine and N-acetylcysteine. Pulm Pharmacol Ther 2005; 18: 367-373.
9. SOGUT S, OZYURT H, ARMUTCU F, KART L, IRAZ M, AKYOL O, OZEN S, KAPLAN S, TEMEL I, YILDIRIM Z. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2004; 494: 213-220.
10. YILDIRIM Z, TURKOZ Y, KOTUK M, ARMUTCU F, GUREL A, IRAZ M, OZEN S, AYDOGDU I, AKYOL O. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 2004; 11: 156-165.
11. IRAZ M, ERDOGAN H, KOTUK M, YAGMURCA M, KILIC T, ERMIS H, FADILLIOGLU E, YILDIRIM Z. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacol Res 2006; 53: 310-316.
12. KING TE JR, BEHR J, BROWN KK, DU BOIS RM, LANCASTER L, DE ANDRADE JA, STAHLER G, LECONTE I, ROUX S, RAGHU G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
13. AYTEMUR ZA, HACIEVLIYAGIL SS, IRAZ M, SAMDANCI E, OZEROL E, KUKU I, NURKABULOV Z, YILDIZ K. Effects of iloprost on bleomycin-induced pulmonary fibrosis in rats compared with methyl-prednisolone. Rev Port Pneumol 2012; 18: 272-277.
14. FELDMAN M, BONDESON J, BRENNAN FM, FOXWELL BM, MAINI RN. The rational for current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits on anti-TNFalpha and minimize hazards? Ann Rheum Dis 1999; 58: 127-131.
15. ADAMSON IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976; 16: 119-125.
16. UMEZAWA H, ISHIZUKA M, MAEDA K, TAKEUCHI T. Studies on bleomycin. Cancer 1967; 20: 891-895.
17. CLAUSSEN CA, LONG EC. Nucleic Acid recognition by metal complexes of bleomycin. Chem Rev 1999; 99: 2797-2816.
18. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
19. GRANDE NR, PEAO MND, DE SA CM, AGUAS AP. Lung fibrosis induced by bleomycin: Structural changes and overview of recent advances. Scanning Microscopy 1998; 12: 487-494.
20. PERLIN AS, SUZUKI S. The structure of lichen in: selective enzymolysis studies. Can J Chem 1962; 40: 50-56.
21. WOOD P. Evaluation of oat bran as a soluble fibre source. Characterization of oat beta-glucan and its effects on glycaemic response. Carbohydrate Polymers 1994; 25: 331-336.
22. WOOD PJ. Cereal beta-glucans in diet and health. J Cereal Sci 2007; 46: 230-238.
23. TOSH SM, BRUMMER Y, WOOD PJ, WANG Q, WEISZ J. Evaluation of structure in the formation of gels by structurally diverse (1-3)(1-4)-beta-D-glucans from four cereal and one lichen species. Carbohydrate Polymers 2004; 57: 249-259.
24. IRAZ M, IRAZ M, ESREFOGLU M, AYDIN MS. Protective effect of β-glucan on acute lung injury induced by lipopolysaccharide in rats. Turk J Med Sci 2015; 45: 261-267.
25. LIANG J, MELICAN D, CAFRO L, PALACE G, FISETTE L, ARMSTRONG R, PATCHEN ML. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 1998; 20: 595-614.
26. CLEARY JA, KELLY GE, HUSBAND AJ. The effect of molecular weight and beta-1, 6-linkages on priming of macrophage function in mice by (1, 3)-beta-Dglucan. Immunol Cell Biol 1999; 77: 395-403.
27. BABAYIGIT H, KUCUK C, SOZUER E, YAZICI C, KOSE K, AKGUN H. Protective effect of beta-glucan on lung injury after cecal ligation and puncture in rats. Intens Care Med 2005; 31: 865-870.
28. CHEN J, SEVIOUR R. Medicinal importance of fungal beta-(1 →3), (1 →6)-glucans. Mycol Res 2007; 111: 635-652.
29. NOVAK M, VETVICKA V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets 2009; 9: 67-75.
30. TSUKADA C, YOKOYAMA H, MIYAJI C, ISHIMOTO Y, KAWAMURA H, ABO T. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol 2003; 221: 1-5.
31. THE PRINCIPLES OF LABORATORY ANIMAL CARE FORMULATED BY THE NATIONAL INSTITUTES OF HEALTH. National Institute of Health publication no. 96-23, revised 1996.
32. ASHCROFT T, SIMPSON JM, TIMBRELL V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470.
33. WOESSNER JF Jr. The determination of hydroxyproline in tissue and protein samples containing small propor tions of this imino acid. Arch Biochem Biophys 1961; 93: 440-447.
34. ESTERBAUER H, CHEESEMAN KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407-421.
35. CORTAS NK, WAKID NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990; 36: 1440-1443.
36. BEUTLER E, DURAN O, DUARTE BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 51: 882-888.
37. PAGLIA DE, VALENTINE WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
38. WEI H, FRENKEL K. Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993; 14: 1195-1201.
39. AEBI H, WYSS SR, SCHERZ B, SKVARIL F. Heterogeneity of erythrocyte catalase II. Isolation and characterization of normal and variant erythrocyte catalase and their subunits. Eur J Biochem 1974; 48: 137-145.
40. SUN Y, OBERLEY LW, LI Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497-500.
41. MOELLER A, ASK K, WARBURTON D, GAULDIE J, KOLB M. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382.
42. MASON RJ, SCHWARZ MI, HUNNINGHAKE GW, MUSSON RA. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med 1999; 160: 1771-1777.
43. BOROK Z, BUHL R, GRIMES GJ, BOKSER AD, HUBBARD RC, HOLROYD KJ, ROUM JH, CZERSKI DB, CANTIN AM, CRYSTAL RG. Effect of glutathione aerosol on oxidant- antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-216.
44. BEHR J, MAIER K, KROMBACH F, ADELMANN-GRILL BC. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis 1991; 144: 146-150.
45. SLEIJFER S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-624.
46. VALKO M, RHODES CJ, MONCOL J, IZAKOVIC M, MAZUR M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40.
47. OKUTAN H, SAVAS C, OZGUNER IF, YONDEN Z, EREN VC, DELIBAS N. Lung injury after aortic occlusionreperfusion in rats: The role of gadolinium chloride. Tohoku J Exp Med 2004; 203: 267-273.
48. SOMUNCU S, CAKMAK M, ERDOGAN S, CAGLAYAN O, CAGLAYAN F, AKMAN H, ULUSOY S, KAYA M. Protective effects of trapidil in lung after abdominal aorta induced ischemia-reperfusion injury: an experimental study. Pediatr Surg Int 2005; 21: 983-988.
49. SENER G, TOKLU H, ERCAN F, ERKANLI G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol 2005; 5: 1387-1396.
50. SENER G, TOKLU HZ, CETINEL S. β-Glucan protects against chronic nicotine-induced oxidative damage in rat kidney and bladder. Environ Toxicol Pharmacol 2007; 23: 25-32.
51. TOKLU HZ, SENER G, JAHOVIC N, USLU B, ARBAK S, YEGEN BC. Beta-glucan protects against burn-induced oxidative organ damage in rats. Int Immunopharmacol 2006; 6: 156-169.
52. GULMEN S, KIRIS I, KOCYIGIT A, DOGUS DK, CEYLAN BG, METEOGLU I. β-Glucan protects against lung injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res 2010; 164: 325-332.
53. BROWN GD, TAYLOR PR, REID DM, WILLMENT JA, WILLIAMS DL, MARTINEZ-POMARES L, WONG SY, GORDON S. Dectin-1 is a major β-glucan receptor on macrophages. J Exp Med 2002; 196: 407-412.
54. ROSS GD, VETVICKA V, YAN J, XIA Y, VETVICKOVA J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999; 42: 61-74.
55. WILLMENT JA, GORDON S, BROWN GD. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem 2001; 276: 43818-43823.
56. BROWN GD, HERRE J, WILLIAMS DL, WILLMENT JA, MARSHALL AS, GORDON S. Dectin-1 mediates the biological effects of β-glucans. J Exp Med 2003; 197: 1119-1124.
57. RICE PJ, KELLEY JL, KOGAN G, ENSLEY HE, KALBFLEISCH JH, BROWDER IW, WILLIAMS DL. Human monocyte scavenger receptors are pattern recognition receptors for (1->3)-beta-D-glucans. J Leukoc Biol 2002; 72: 140-146.
58. JEFFCOATE WJ, PRICE P, HARDING KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20: 78-89.
59. ENGSTAD CS, ENGSTAD RE, OLSEN JO, OSTERUD B. The effect of soluble beta-1, 3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int Immunopharmacol 2002; 2: 1585-1597.
60. DEMIR G, KLEIN HO, MANDEL-MOLINAS N, TUZUNER N. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 2007; 7: 113-116.
61. KWON AH, QIU Z, HASHIMOTO M, YAMAMOTO K, Kimura T. Effects of medicinal mushroom (Sparassis crispa) on wound healing in streptozotocin- induced diabetic rats. Am J Surg 2009; 197: 503-509.
62. BROWDER W, WILLIAMS D, LUCORE P, PRETUS H, JONES E, MCNAMEE R. Effect of enhanced macrophage function on early wound healing. Surgery 1988; 104: 224-230.
63. WEI D, ZHANG L, WILLIAMS DL, BROWDER IW. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen 2002; 10: 161-168.
64. OZKAN OV, OZTURK OH, AYDIN M, YILMAZ N, YETIM I, NACAR A, OKTAR S, SOGUT S. Effects of β-glucan pretreatment on acetylsalicylic acid-induced gastric damage: An experimental study in rats. Curr Ther Res Clin Exp 2010; 71: 369-383.
65. BAYINDIR T, FILIZ A, IRAZ M, KAYA S, TAN M, KALCIOGLU MT. Evaluation of the protective effect of Beta glucan on amikacin ototoxicity using distortion product otoacoustic emission measurements in rats. Clin Exp Otorhinolaryngol 2013; 6: 1-6.
66. MITCHELL JR, JOLLOW DJ, POTTER WZ, GILLETTE JR, BRODIE BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187: 211-217.